Aptevo Therapeutics (APVO) Operating Leases (2019 - 2026)
Aptevo Therapeutics (APVO) posted Operating Leases of $3.5 million for Q1 2026, down 6.19% sequentially from $3.8 million in Q4 2025, and down 19.77% YoY from $4.4 million in Q1 2025.
Aptevo Therapeutics (APVO) Operating Leases (2019 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Operating Leases for 8 years, with the latest figure at $3.5 million in Q1 2026.
- Quarterly Operating Leases fell 19.77% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 19.77% YoY) and the FY2025 annual result came in at $3.8 million, down 18.2% from the prior year.
- Operating Leases eased to $3.5 million in Q1 2026 per APVO's latest filing, from $3.8 million in the prior quarter.
- Over five years, Operating Leases peaked at $6.4 million in Q2 2022 and troughed at $1.1 million in Q1 2022.
- A 5-year average of $4.8 million and a median of $5.0 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2023: Operating Leases tumbled 49.74% in 2022, then soared 453.99% in 2023.
- Over 5 years, Operating Leases stood at $6.1 million in 2022, then fell by 11.48% to $5.4 million in 2023, then dropped by 14.81% to $4.6 million in 2024, then slipped by 18.2% to $3.8 million in 2025, then retreated by 6.19% to $3.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $3.5 million, $3.8 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Aptevo Therapeutics | 3.19 Mn | -6.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.30 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 3.76 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 4.60 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 5.20 Mn |
| Dec 31, 2023 | 5.40 Mn |
| Sep 30, 2023 | 5.60 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | 5.90 Mn |
| Dec 31, 2022 | 6.10 Mn |
| Sep 30, 2022 | 6.24 Mn |
| Jun 30, 2022 | 6.39 Mn |
| Mar 31, 2022 | 1.07 Mn |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 1.61 Mn |